These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
486 related articles for article (PubMed ID: 30266938)
1. Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis. Zhao X; Zhu Y; Hu J; Jiang L; Li L; Jia S; Zen K Sci Rep; 2018 Sep; 8(1):14517. PubMed ID: 30266938 [TBL] [Abstract][Full Text] [Related]
2. Lapachol inhibits glycolysis in cancer cells by targeting pyruvate kinase M2. Shankar Babu M; Mahanta S; Lakhter AJ; Hato T; Paul S; Naidu SR PLoS One; 2018; 13(2):e0191419. PubMed ID: 29394289 [TBL] [Abstract][Full Text] [Related]
3. Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway. Dai Y; Liu Y; Li J; Jin M; Yang H; Huang G Bioengineered; 2022 May; 13(5):13906-13918. PubMed ID: 35706397 [TBL] [Abstract][Full Text] [Related]
4. Shikonin differentially regulates glucose metabolism via PKM2 and HIF1α to overcome apoptosis in a refractory HCC cell line. Yang W; Liu J; Hou L; Chen Q; Liu Y Life Sci; 2021 Jan; 265():118796. PubMed ID: 33220292 [TBL] [Abstract][Full Text] [Related]
5. Shikonin inhibits growth, invasion and glycolysis of nasopharyngeal carcinoma cells through inactivating the phosphatidylinositol 3 kinase/AKT signal pathway. Zhang J; Zhou J; Xiao S Anticancer Drugs; 2020 Oct; 31(9):932-941. PubMed ID: 32282369 [TBL] [Abstract][Full Text] [Related]
6. Shikonin inhibits thyroid cancer cell growth and invasiveness through targeting major signaling pathways. Yang Q; Ji M; Guan H; Shi B; Hou P J Clin Endocrinol Metab; 2013 Dec; 98(12):E1909-17. PubMed ID: 24106286 [TBL] [Abstract][Full Text] [Related]
7. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Chen J; Xie J; Jiang Z; Wang B; Wang Y; Hu X Oncogene; 2011 Oct; 30(42):4297-306. PubMed ID: 21516121 [TBL] [Abstract][Full Text] [Related]
8. Shikonin inhibits the Warburg effect, cell proliferation, invasion and migration by downregulating PFKFB2 expression in lung cancer. Sha L; Lv Z; Liu Y; Zhang Y; Sui X; Wang T; Zhang H Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34109434 [TBL] [Abstract][Full Text] [Related]
9. Shikonin Inhibits Tumor Growth of ESCC by suppressing PKM2 mediated Aerobic Glycolysis and STAT3 Phosphorylation. Zhang Q; Liu Q; Zheng S; Liu T; Yang L; Han X; Lu X J Cancer; 2021; 12(16):4830-4840. PubMed ID: 34234853 [No Abstract] [Full Text] [Related]
10. Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer. Chao TK; Huang TS; Liao YP; Huang RL; Su PH; Shen HY; Lai HC; Wang YC PLoS One; 2017; 12(7):e0182166. PubMed ID: 28753677 [TBL] [Abstract][Full Text] [Related]
11. Inhibiting aerobic glycolysis suppresses renal interstitial fibroblast activation and renal fibrosis. Ding H; Jiang L; Xu J; Bai F; Zhou Y; Yuan Q; Luo J; Zen K; Yang J Am J Physiol Renal Physiol; 2017 Sep; 313(3):F561-F575. PubMed ID: 28228400 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin. Wang X; Zhang F; Wu XR Sci Rep; 2017 Apr; 7():45983. PubMed ID: 28378811 [TBL] [Abstract][Full Text] [Related]
13. Beta-elemene inhibits breast cancer metastasis through blocking pyruvate kinase M2 dimerization and nuclear translocation. Pan Y; Wang W; Huang S; Ni W; Wei Z; Cao Y; Yu S; Jia Q; Wu Y; Chai C; Zheng Q; Zhang L; Wang A; Sun Z; Huang S; Wang S; Chen W; Lu Y J Cell Mol Med; 2019 Oct; 23(10):6846-6858. PubMed ID: 31343107 [TBL] [Abstract][Full Text] [Related]
14. Tumor M2-PK: A novel urine marker of bladder cancer. Liu W; Woolbright BL; Pirani K; Didde R; Abbott E; Kaushik G; Martin P; Hamilton-Reeves J; Taylor JA; Holzbeierlein JM; Anant S; Lee EK PLoS One; 2019; 14(6):e0218737. PubMed ID: 31246990 [TBL] [Abstract][Full Text] [Related]
15. Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. Shi HS; Li D; Zhang J; Wang YS; Yang L; Zhang HL; Wang XH; Mu B; Wang W; Ma Y; Guo FC; Wei YQ Cancer Sci; 2010 Jun; 101(6):1447-53. PubMed ID: 20507318 [TBL] [Abstract][Full Text] [Related]
17. Interdependence of GLO I and PKM2 in the Metabolic shift to escape apoptosis in GLO I-dependent cancer cells. Shimada N; Takasawa R; Tanuma SI Arch Biochem Biophys; 2018 Jan; 638():1-7. PubMed ID: 29225125 [TBL] [Abstract][Full Text] [Related]
18. Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway. Tang JC; Ren YG; Zhao J; Long F; Chen JY; Jiang Z Life Sci; 2018 Jul; 204():71-77. PubMed ID: 29738778 [TBL] [Abstract][Full Text] [Related]
19. [Antitumor effect research progress of shikonin and its derivatives]. Zhu MY; Wang RB; Zhou W; Li SS Yao Xue Xue Bao; 2012 May; 47(5):588-93. PubMed ID: 22812000 [TBL] [Abstract][Full Text] [Related]
20. Shikonin reverses cancer-associated fibroblast-induced gemcitabine resistance in pancreatic cancer cells by suppressing monocarboxylate transporter 4-mediated reverse Warburg effect. Hu X; Peng X; Zhang Y; Fan S; Liu X; Song Y; Ren S; Chen L; Chen Y; Wang R; Peng J; Shen X; Chen Y Phytomedicine; 2024 Jan; 123():155214. PubMed ID: 38134861 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]